Neogen Chemicals (NEOGEN) Q2 FY27 Results: Battery Sales ₹37 Cr

Neogen Chemicals (NSE: NEOGEN) - Share price: ₹2,213 (3 November 2026, screener.in) - Market cap: ₹6,648 crore (3 November 2026, screener.in) - P/E: about 164x (3 November 2026, screener.in) - ROCE: 6.46% (3 November 2026, screener.in)

Neogen Chemicals (NEOGEN) Q2 FY27 results: sales rose 42% in the September 2026 quarter and battery chemical sales grew from ₹5 crore to ₹37 crore.

The company is also building a large battery-materials business that sold ₹37 crore in the quarter, up from ₹5 crore a year earlier. Here is what the company's own investor presentation says, and what could go wrong.

Where Neogen Chemicals (NEOGEN) growth comes from

Neogen Chemicals is an Indian specialty chemicals maker, incorporated in 1989 and listed on the NSE and BSE mainboard. It has three businesses:

- Organic chemicals: bromine compounds, organolithium (a reactive lithium-based chemical used to make medicines), advanced intermediates and custom manufacturing for drug, farm-chemical, fragrance and electronics customers. - Inorganic chemicals: lithium-based products used in air-conditioning gases, medicines, specialty plastics and batteries. - Battery chemicals: battery electrolytes and electrolyte salts, made by its wholly owned subsidiary Neogen Ionics.

The company says it has imported lithium carbonate into India for 30 years. It also has a technology partnership with Japan's Morita group for electrolytes and salts. It runs 7 factories and 2 research centres with 1,058 employees. In the September quarter, 66% of sales came from India and 34% from exports.

Neogen Chemicals Q2 FY27 results: the September 2026 quarter in numbers

Consolidated, ₹ crore Q2 FY27 Q2 FY26 Change ------------ Sales 296 208.7 +42% EBITDA 45.3 – +51% EBITDA margin 15.3% 14.4% +95 bps Net profit 8.2 3.4 +144% Earnings per share (₹) 2.96 1.28 +131%

For the first half (April to September 2026), sales were ₹546.3 crore (+38%), EBITDA was ₹93.6 crore (+52%) and net profit was ₹25.3 crore (+86%).

Segment sales for the September quarter:

Segment, ₹ crore Q2 FY27 Q2 FY26 Change ------------ Organic chemicals 238 184 +29% Inorganic chemicals 58 24 +140% Battery chemicals 37 5 +585%

Neogen Chemicals margin: the core business earns more on each rupee

The standalone company is the older chemicals business, without the battery subsidiary. Its numbers show the margin gain clearly:

- EBITDA margin: 18.6% in the September quarter against 16.9% a year earlier (+174 bps). For the first half it was 18.9% against 17.8%. - Sales: ₹288 crore in the quarter (+39%). - Net profit: ₹21.1 crore (+127%). - Why: management links the gain to higher volumes spread over fixed costs in the organic and inorganic segments.

The consolidated margin is lower, at 15.3% in the quarter. The battery subsidiary carries fixed costs while its sales are still small. Management calls this the foundation for future gains as that business fills its factories.

Neogen Chemicals capacity: what is being built

- Organolithium, Patancheru: the board approved a rise from 300 to 600 tonnes a year, at a cost of up to ₹45 crore. Management sees extra sales of ₹150 to ₹200 crore, depending on lithium prices. No completion date was given. - Battery electrolyte salts, Dahej: 1,000 tonnes a year were commissioned in the quarter, on top of 200 tonnes earlier. Another 300 tonnes are in trial production. A further 1,000 tonnes of salts and 500 tonnes of an intermediate are due in the second half of FY27. Project completion is targeted for February 2027. - Battery electrolyte, Dahej: the 2,000-tonne plant is built and in trial runs. Domestic battery makers are still validating it. Recipes have come from 5 to 6 large battery factories, with joint trials under way. - Pakhajan, new site: 30,000 tonnes of electrolyte and 3,000 tonnes of salts, with a budget of ₹1,367 crore. Completion is expected in March 2027. - Total plan for Neogen Ionics: 32,000 tonnes of electrolyte and 5,500 tonnes of salts across both sites. Of the ₹1,795 crore budget, ₹1,537 crore has been spent.

The company has provisional approvals for its salts from 5 large international customers. Commercial supply has started with 2 of them.

Neogen Chemicals management's plans

These are the company's own forward-looking statements. They are not facts and not promises.

- Full-year FY27 guidance is "on track". The presentation gives no number. - A "substantial scale-up" of battery chemicals is expected from the March 2027 quarter, as domestic battery plants start and US electrolyte makers move to suppliers outside the restricted countries before the 2027 US deadline. - The October to March half is usually stronger than April to September. Reasons given: European demand picks up from October, lithium demand for cooling products rises in the March quarter, and farm chemicals are seasonal. - Managing Director Dr. Harin Kanani said: "We expect a substantial scale-up in Q4 FY27 and beyond... establishing Neogen as one of the largest Indian battery component manufacturers."

Neogen Chemicals balance sheet: growth funded by debt, then by new shares

What to remember Sales are growing fast and the core margin is rising. But the company has spent over ₹1,500 crore on battery plants that have not yet earned a return. Profit has to catch up with the capital used.

Consolidated, ₹ crore FY21 FY22 FY23 FY24 FY25 FY26 --------------------- Sales 336 487 686 691 778 862 EBITDA margin 19.1% 17.8% 16.3% 15.9% 17.5% 15.9% Net profit 31 45 50 36 35 29 Net debt 183 99 265 378 530 1,295

Sales rose 21% a year over five years, but net profit in FY26 was below FY21. The new battery plants caused this: interest and depreciation came first, and the sales are only now starting.

- Share sale: the company raised ₹600 crore in its first qualified institutional placement (QIP). Institutions bid 6.5 times the amount on offer. The money goes to debt repayment and growth. - Net worth: ₹1,578 crore at 30 September 2026, against ₹800 crore a year earlier. - Debt: consolidated total debt is ₹1,560 crore and net debt is ₹1,095 crore. Cash and liquid investments are ₹465 crore. - Interest: ₹27.8 crore in the quarter (+43%), against a net profit of ₹8.2 crore. The company expects interest to fall as the QIP money repays term debt. - Rating: CRISIL moved its outlook to "Stable" from "Negative" and rates the long-term debt A-. - Dahej fire: a fire in March 2025 damaged the Dahej plant. The company has received ₹164 crore of insurance money so far and accepted another ₹152 crore on 29 October 2026. A replacement plant is being built. - Joint venture: a deal is signed to move the electrolyte-salt business into a Morita-backed subsidiary for ₹245 crore. Morita put in ₹77 crore.

How the Neogen Chemicals valuation compares

The share trades at about 164 times its profit of the last twelve months. That is the highest in its peer group on screener.in. Its return on capital employed (ROCE) of 6.46% is among the lowest. A high P/E here prices in the battery business becoming large. Today's profit does not support it.

Company Price (₹) P/E Market cap (₹ crore) Latest quarter sales growth ROCE ------------------ Neogen Chemicals 2,212.85 164.5 6,648 +41.8% 6.5% Pidilite Industries 1,507.75 57.2 1,53,570 +20.9% 31.0% Gujarat Fluorochemicals 4,561.00 81.1 50,103 +24.0% 9.6% Navin Fluorine 8,467.90 47.4 43,453 +57.0% 21.0% Deepak Nitrite 1,536.20 19.6 20,953 +61.8% 11.4% Aether Industries 1,504.25 79.2 19,966 +24.0% 11.9% Aarti Industries 448.30 26.8 16,262 +74.7% 6.9% Fine Organic 5,170.10 32.9 15,851 +22.1% 21.5%

Source: screener.in peer table, 3 November 2026. Screener shows a 52-week range of ₹967 to ₹2,785 for Neogen.

Neogen Chemicals risks

- Fixed costs in the battery unit: consolidated net margin was only 2.8% in the quarter, against 7.3% for the standalone company. Gains come later, as the battery plants fill up. - Customer approvals: domestic battery makers are still validating the electrolyte plant. The company gives no firm date for these approvals. - Input costs: feedstock prices are rising and press on gross margin. Conflict in the Middle East adds supply and freight problems. - Dahej plant: the replacement plant is not yet running. Until it is, the company pays for tolling (outside factories making its products), which adds cost. - Interest and depreciation: these keep rising with the capital spending until QIP money repays debt. - US policy: the plan to supply US electrolyte makers depends on US rules about restricted-country supply chains and tax credits. A change in these rules could delay that demand. - Valuation: at about 164 times profit, any miss in the battery ramp-up can hurt the share price.

Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.

Sources

- https://nsearchives.nseindia.com/corporate/NEOGEN01112026233447EPfinal.pdf